1. Anti-infection
    Metabolic Enzyme/Protease
  2. HCV
    HCV Protease

Elbasvir (Synonyms: MK-8742)

Cat. No.: HY-15789 Purity: 98.20%
Data Sheet SDS Handling Instructions

Elbasvir is a small-molecule inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) being developed as a component of treatment regimens for chronic HCV infection.

For research use only. We do not sell to patients.
Elbasvir Chemical Structure

Elbasvir Chemical Structure

CAS No. : 1370468-36-2

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $146 In-stock
2 mg $80 In-stock
5 mg $110 In-stock
10 mg $150 In-stock
50 mg $490 In-stock
100 mg $850 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Elbasvir is a small-molecule inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) being developed as a component of treatment regimens for chronic HCV infection.

In Vitro

Elbasvir shows potent activity against genotype 1a and 1b replicons, with EC90 of 0.006 nM for both the wild-type 1a_H77 and 1b_con1 replicons. Elbasvir inhibits genotype 3 replicons with EC90 of 0.12 nM. Elbasvir (0.06 nM, 0.6 nM, and 6 nM) demonstrates dose-dependent suppression of resistant genotype 1a replicons, illustrated by the reductions in colony counts at higher doses[1]. Elbasvir is highly potent against HCV replicons bearing NS5A sequences from GT1a, -1b, -2a(31L), -3a, -4a, -5a, and -6, with EC50s in the low-picomolar range[2].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02973503 University Hospital, Clermont-Ferrand|Merck Sharp & Dohme Corp.|LC2 PHARMA Chronic HCV Infection November 2016 Phase 3
NCT03144635 Kyushu University|Merck Sharp & Dohme Corp. Hepatitis C Viral|Chronic Kidney Disease stage3 April 1, 2017 Phase 4
NCT03098121 Taoyuan General Hospital|Merck Sharp & Dohme Corp. To Assess the Efficacy of Grazoprevir 100mg and Elbasvir 50mg by Determining the Proportion of Sustained Virological Response 12 Weeks After the End of Therapy June 20, 2017 Phase 4
NCT02940691 Kirby Institute Hepatitis C December 2016 Phase 4
NCT03222167 Institute Of Cardiology & Internal Diseases, Kazakhstan|Schering-Plough|Synergy Research Group Chronic Hepatitis C Genotype 1B|Metabolic Syndrome|Fibrosis, Liver|Cirrhoses, Liver October 2017 Phase 3
NCT02600325 Erasmus Medical Center Acute Hepatitis C|Human Immunodeficiency Virus|Hepatitis C February 2016 Phase 3
NCT03145623 University Hospital, Toulouse|MSD France Hepatitis C|Chronic Kidney Diseases June 2, 2017
NCT02105662 Merck Sharp & Dohme Corp. Chronic Hepatitis C June 2014 Phase 3
NCT02945150 Massachusetts General Hospital|Merck Sharp & Dohme Corp. Renal Failure February 1, 2017 Phase 4
NCT02902120 University of Maryland Hepatitis C|Renal Insufficiency, Chronic|Disorder of Transplanted Kidney May 1, 2017 Phase 4
NCT03022006 Norte Study Group|Merck Sharp & Dohme Corp. Chronic Hepatitis C January 15, 2017 Phase 4
NCT02886624 Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba|Merck Sharp & Dohme Corp.|Institut National de la Santé Et de la Recherche Médicale, France Acute Hepatitis C|HIV May 24, 2017 Phase 2
NCT03111966 Hepa C Hepatitis C March 31, 2017
NCT02647632 French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) Hepatitis C January 2016 Phase 2
NCT03026023 Raymond T. Chung, MD|Merck Sharp & Dohme Corp.|Massachusetts General Hospital Cardiac Transplant Disorder|Hepatitis C December 1, 2017 Phase 4
NCT02251990 Merck Sharp & Dohme Corp. Hepatitis C January 28, 2015 Phase 3
NCT03110055 Tel-Aviv Sourasky Medical Center|Merck Sharp & Dohme Corp. HCV, HCC May 1, 2017
NCT01797536 Merck Sharp & Dohme Corp.|Celerion Hepatic Insufficiency March 2013 Phase 1
NCT02252016 Merck Sharp & Dohme Corp. Hepatitis C October 22, 2014 Phase 3
NCT02105688 Merck Sharp & Dohme Corp. Chronic Hepatitis C September 2, 2014 Phase 3
NCT02105701 Merck Sharp & Dohme Corp. Hepatitis C Infection June 2014 Phase 3
NCT01532973 Merck Sharp & Dohme Corp. Hepatitis, Viral, Human February 2012 Phase 1
NCT01937975 Merck Sharp & Dohme Corp. Chronic Hepatitis C|Renal Impairment September 2013 Phase 1
NCT03105349 Fundacion SEIMC-GESIDA HCV July 15, 2017 Phase 4
NCT02601573 Merck Sharp & Dohme Corp. Hepatitis C January 2016 Phase 2
NCT02204475 Merck Sharp & Dohme Corp. Hepatitis C November 2014 Phase 3
NCT02358044 Merck Sharp & Dohme Corp. Hepatitis C February 27, 2015 Phase 3
NCT02133131 Merck Sharp & Dohme Corp. Hepatitis C June 2014 Phase 2
NCT02105467 Merck Sharp & Dohme Corp. Chronic Hepatitis C Virus June 2014 Phase 3
NCT02203149 Merck Sharp & Dohme Corp. Hepatitis C August 2014 Phase 2|Phase 3
NCT02092350 Merck Sharp & Dohme Corp. Hepatitis C Virus March 2014 Phase 2|Phase 3
NCT02785666 University of Zurich Hepatitis C|HIV June 2016 Phase 3
NCT01932762 Merck Sharp & Dohme Corp. Hepatitis C October 2013 Phase 2
NCT02105454 Merck Sharp & Dohme Corp. Hepatitis C Virus May 2014 Phase 2
NCT01717326 Merck Sharp & Dohme Corp. Hepatitis C February 2013 Phase 2
NCT03093415 Oregon Health and Science University Hepatitis C|Substance Use Disorders|Substance Abuse, Intravenous May 30, 2017 Phase 4
NCT02890719 Fundacion Clinic per a la Recerca Biomédica Liver Transplantation|Hepatitis C September 2016 Phase 3
NCT02115321 Merck Sharp & Dohme Corp. Chronic Hepatitis C May 2014 Phase 2|Phase 3
NCT02332707 Merck Sharp & Dohme Corp. Hepatitis C January 22, 2015 Phase 2
NCT02332720 Merck Sharp & Dohme Corp. Hepatitis C January 28, 2015 Phase 2
NCT02897596 Fundacion Clinic per a la Recerca Biomédica Hepatitis C|HIV September 2016 Phase 3
NCT02786537 University of Florida|Patient-Centered Outcomes Research Institute|Merck Sharp & Dohme Corp.|AbbVie Chronic Hepatitis C June 2016 Phase 4
NCT02333292 Valme University Hospital|Hospital del SAS de Jerez|Hospital General Universitario Elche|Hospital La Línea de la Concepción|Complexo Hospitalario Universitario de A Coruña|Hospital de Figueres|Hospital Universitario Puerto Real|Hospital Universitario Virgen de la Victoria|Hospital Universitario de Canarias|Hospital General Universitario de Alicante|Hospital Universitario Araba|Hospital Royo Vilanova|Hospital Universitario de Burgos|Complejo Hospitalario Universitario de Huelva|Hospital Universitario Reina Sofia|Hospital Universitario Virgen Macarena|Complexo Hospitalario Universitario de Vigo|Clinica Universidad de Navarra, Universidad de Navarra|Hospital Clinico Universitario San Cecilio|Hospital Universitario La Fe|Hospital General Universitario de Valencia|Hospital Universitario Infanta Leonor|Hospital Universitario de Gran Canaria|Hospital General Universitario Santa Lucía|Centro Penitenciario Alicante 1|Hospital Regional Universitario Carlos Haya|Hospital Virgen de la Luz|Hospital General Universitario de Castellón|Hospital Parc Taulí, Sabadell Chronic Hepatitis C Infection December 2014
NCT02732405 Istituto Clinico Humanitas|CD Pharma Group S.r.l. Hepatitis C|Compensated Cirrhosis May 2016 Phase 3
View MoreCollapse
References
Molecular Weight

882.02

Formula

C₄₉H₅₅N₉O₇

CAS No.

1370468-36-2

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Elbasvir
Cat. No.:
HY-15789
Quantity: